Jane Street Group, LLC Clovis Oncology, Inc. Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.85 $49,435 - $134,180	-47,081 Reduced 47.23%	52,609 $63,000
Q2 2022 Aug 16, 2022	SELL	$0.63 - $2.96 $185,358 - $870,891	-294,220 Reduced 74.69%	99,690 $180,000
Q1 2022 May 17, 2022	BUY	$1.43 - $3.14 $283,044 - $621,509	197,933 Added 101.0%	393,910 $796,000
Q4 2021 Feb 15, 2022	SELL	$2.7 - $4.76 $83,297 - $146,850	-30,851 Reduced 13.6%	195,977 $531,000
Q3 2021 Nov 16, 2021	SELL	$4.06 - $5.8 $533,252 - $761,789	-131,343 Reduced 36.67%	226,828 $1.01 Million
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $1.27 Million - $1.79 Million	253,540 Added 242.32%	358,171 $2.08 Million
Q1 2021 May 18, 2021	SELL	$4.81 - $10.34 $346,546 - $744,965	-72,047 Reduced 40.78%	104,631 $735,000
Q4 2020 Feb 17, 2021	BUY	$4.13 - $6.41 $362,291 - $562,298	87,722 Added 98.61%	176,678 $849,000
Q3 2020 Nov 17, 2020	BUY	$4.82 - $7.72 $217,232 - $347,932	45,069 Added 102.69%	88,956 $519,000
Q1 2020 May 15, 2020	SELL	$3.77 - $11.0 $800,125 - $2.33 Million	-212,235 Reduced 82.86%	43,887 $279,000
Q4 2019 Feb 14, 2020	BUY	$3.0 - $16.43 $731,904 - $4.01 Million	243,968 Added 2007.31%	256,122 $2.67 Million
Q3 2019 Nov 14, 2019	SELL	$3.93 - $15.35 $109,772 - $428,756	-27,932 Reduced 69.68%	12,154 $47,000
Q2 2019 Aug 15, 2019	SELL	$12.81 - $25.67 $50,637 - $101,473	-3,953 Reduced 8.98%	40,086 $596,000
Q1 2019 May 16, 2019	SELL	$17.66 - $30.28 $426,842 - $731,867	-24,170 Reduced 35.44%	44,039 $1.09 Million
Q4 2018 Feb 15, 2019	BUY	$11.63 - $32.67 $521,186 - $1.46 Million	44,814 Added 191.55%	68,209 $1.23 Million
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $156,160 - $263,085	5,317 Added 29.41%	23,395 $687,000
Q2 2018 Aug 15, 2018	BUY	$42.06 - $62.4 $331,979 - $492,523	7,893 Added 77.5%	18,078 $822,000
Q1 2018 May 15, 2018	SELL	$50.12 - $67.72 $547,109 - $739,231	-10,916 Reduced 51.73%	10,185 $538,000
Q4 2017 Feb 15, 2018	SELL	$57.69 - $84.58 $2.99 Million - $4.38 Million	-51,787 Reduced 71.05%	21,101 $1.44 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $4.9 Million - $6.18 Million	72,888	72,888 $6.01 Million

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account